palivizumab RSV Synagis
Selected indexed studies
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. (Pediatrics, 2024) [PMID:39350745]
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. (Cochrane Database Syst Rev, 2021) [PMID:34783356]
- Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review. (Am Fam Physician, 2023) [PMID:37440737]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing. (2024) pubmed
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children. (2021) pubmed
- Palivizumab. (1999) pubmed
- Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). (2024) pubmed
- Respiratory Syncytial Virus Bronchiolitis: Rapid Evidence Review. (2023) pubmed
- Respiratory Syncytial Virus Bronchiolitis in Children. (2017) pubmed
- RSV Prevention in All Infants: Which Is the Most Preferable Strategy? (2022) pubmed
- Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. (2002) pubmed
- A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. (2017) pubmed
- A potent broad-spectrum neutralizing antibody targeting a conserved region of the prefusion RSV F protein. (2024) pubmed